文献速递妇科产科

社区子宫内膜癌队列中致病性胚系变异患病率及检测指征

Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort.
PubMed 文献 · Gynecol Oncol · 2026-10-01

这项基于社区人群的子宫内膜癌研究纳入2016至2022年诊断的10,233例女性,其中14.5%接受了胚系检测,检测阳性率为16.9%。加权估计总体人群中致病性胚系变异患病率为11.9%,Lynch综合征相关变异占1.7%,同源重组缺陷相关变异占4.7%。诊断时检测发现了74%的阳性病例,但仅覆盖约半数HRD相关变异。

要点

  • 社区子宫内膜癌人群中致病性胚系变异估计患病率为11.9%。
  • Lynch综合征相关变异占1.7%,HRD相关变异占4.7%。
  • 诊断时检测可发现74%阳性病例,但HRD变异仅约半数被检出。

核心结论

  • 在基于人群的子宫内膜癌队列中,致病性胚系变异估计患病率为11.9%,其中Lynch相关1.7%、HRD相关4.7%。
  • 诊断时检测占所有阳性病例的约四分之三,覆盖大多数Lynch但仅约半数HRD相关变异。
  • Lynch相关致病性胚系变异在亚洲患者中更常见。

研究设计与样本

  • 基于社区人群的子宫内膜癌队列研究,纳入2016至2022年诊断的患者。
  • 共10,233例女性,其中1,487例(14.5%)接受了胚系检测。
  • 采用倾向评分加权估计总体队列中致病性胚系变异患病率。

主要发现

  • 接受检测者中251例(16.9%,95% CI: 15.0-18.9%)检测阳性。
  • 64例(4.3%,95% CI: 3.4-5.5%)携带HRD相关变异(BRCA1、BRCA2、ATM、BRIP1、RAD51C、RAD51D、PALB)。
  • 134例(9.0%,95% CI: 7.6-10.6%)携带Lynch综合征相关变异(MSH6、PMS2、MLH1、MLH2或EPCAM)。
  • 诊断时检测占阳性病例的74%,包括89.6%的Lynch和54.7%的HRD相关变异。
  • 总体估计患病率11.9%(95% CI: 9.6-14.6%),Lynch 1.7%(95% CI: 1.4-2.2%),HRD相关4.7%(95% CI: 3.3-6.7%)。

临床怎么用

  • 子宫内膜癌诊断时应考虑胚系检测以识别Lynch综合征和HRD相关变异。
  • 诊断时检测可发现大多数Lynch综合征,但HRD相关变异可能需额外检测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the prevalence of pathogenic germline variants (gPVs) and indications for testing in a diverse community-based endometrial cancer population. METHODS: Among patients diagnosed from 2016 to 2022, the prevalence of gPVs was determined and detection rates compared by indication. Propensity score weighting was used to estimate gPV prevalence in the overall endometrial cancer cohort. RESULTS: Among 10,233 women, 1487 (14.5%) underwent germline testing: at diagnosis for 997 (67%), recurrence for 90 (6.1%), diagnosis of breast, colon, or lung cancer for 71 (4.8%), and at another time for 329 (22%). Among those tested, 251 (16.9%, 95% CI: 15.0-18.9%) tested positive, including 64 (4.3%, 95% CI: 3.4-5.5%) with variants related to homologous recombination deficiency (HRD) (BRCA1, BRCA2, ATM, BRIP1, RAD51C, RAD51D, and PALB), and 134 (9.0%, 95% CI: 7.6-10.6%) with Lynch syndrome related mutations (MSH6, PMS2, MLH1, MLH2, or EPCAM). Testing at diagnosis accounted for 74% of patients found to have gPVs, including 89.6% patients with Lynch and 54.7% patients with HRD-related variants. The estimated prevalence of gPVs in the overall endometrial cancer population was 11.9% (95% CI: 9.6-14.6%), including 1.7% (95% CI: 1.4-2.2%) with Lynch and 4.7% (95% CI: 3.3-6.7%) with HRD-related variants. Rates of gPVs did not differ by race, but Lynch variants were more common in Asian patients. CONCLUSION: In a population-based endometrial cancer cohort, the estimated prevalence of gPVs was 11.9%, including 1.7% with Lynch and 4.7% with HRD-related variants. Testing at diagnosis accounted for 3 out of 4 positive cases, including most Lynch but only half of HRD-related variants. Lynch related gPVs were more common among Asian patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Suh-Burgmann E, Finertie H, Hung YY, et al. Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort. Gynecol Oncol. 2026. PMID: 42822083. doi:10.1016/j.ygyno.2026.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。